Egros Fabrice 4
4 · Syndax Pharmaceuticals Inc · Filed Mar 3, 2021
Insider Transaction Report
Form 4
Egros Fabrice
Director
Transactions
- Exercise/Conversion
Common Stock
2021-03-01$7.20/sh+74$533→ 26,241 total - Exercise/Conversion
Stock Options (Right to buy)
2021-03-01−74→ 0 totalExercise: $7.20Exp: 2025-08-18→ Common Stock (0 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2021-03-01−10,167→ 0 totalExercise: $6.35Exp: 2024-12-18→ Common Stock (0 underlying) - Exercise/Conversion
Common Stock
2021-03-01$6.35/sh+10,167$64,560→ 26,167 total - Sale
Common Stock
2021-03-01$24.31/sh−10,167$247,182→ 16,074 total - Sale
Common Stock
2021-03-01$24.31/sh−74$1,799→ 16,000 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 106,926 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $23.84 to $25.15.
- [F3]This option is fully vested.